Clinical Trial Update: Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis

View source ↗

Summary

A completed clinical trial evaluating switching relapsing-remitting multiple sclerosis patients from daily 20 mg glatiramer acetate injections to 40 mg three ti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GLATIRAMER ACETATE (GLATIRAMER ACETATE)

Snippet

Sponsor: University at Buffalo | Conditions: Multiple Sclerosis | Status: COMPLETED